Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061306 · ClinicalTrials.gov registry record
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
A clinical trial of Celiac Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT02061306: Recruiting study of Celiac Disease, sponsored by Massachusetts General Hospital.
NCT02061306 is a study of Celiac Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 500 participants, below the 1,959-participant average among 24 other Celiac Disease trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02061306, a study of Celiac Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of these factors as possible and study how they each contribute to disease development. If the investigators find that any one factor, or combination of factors, increases the risk of developing CD, we will be able to apply this information and help prevent or detect disease in high-risk children in the future.
Primary Outcome
We will use stool samples collected over time to survey the microbial community in order to establish microbiota patterns associated with CD autoimmunity.
Conditions Studied
Study Locations (2)
Massachusetts
- MassGeneral Hospital for Children - Boston
Other
- University of Roma La Sapienza - Rome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2014-03 |
| Est. Completion | 2025-12 |
What NCT02061306 shows while recruiting
NCT02061306 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,959-participant average among 24 other Celiac Disease trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02061306 reports a single indexed study location in Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT02061306 about?
NCT02061306 is a clinical study titled "Celiac Disease Genomic Environmental Microbiome and Metabolomic Study". Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the foods that you eat. In the CDGEMM study, we will consider as many of thes...
What is the current status of trial NCT02061306?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2014-03. Estimated completion is 2025-12.
What conditions does trial NCT02061306 study?
This clinical trial studies the following conditions: Celiac Disease.
Who is sponsoring clinical trial NCT02061306?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02061306 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02061306's enrollment target sits among peer trials
500 4th of 24 higher than 20 of 24 other Celiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
RECRUITING · Phase 1
-
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
RECRUITING
-
Immune Responses to Gluten
RECRUITING · NA
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
-
Urine Metabolites in the Diagnosis of Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia